Courtesy: Focused Ultrasound
Focused ultrasound used to treat depression for first time
October 08, 2015
by Aine Cryts
, Contributing Reporter
The world’s first treatment of a patient with severe depression using focused ultrasound has been performed in Korea, according to the Focused Ultrasound Foundation. Dr. Rees Cosgrove, head of epilepsy and functional neurosurgery at Brigham and Women’s Hospital in Boston, told HCB News the patient was treated on September 19.
The beauty of using focused ultrasound to treat patients with severe depression is you don’t need to do an invasive surgery, said Cosgrove, who has been performing surgery on patients with psychiatric illness since the early 1990s.
Described by the Focused Ultrasound Foundation as a potentially powerful non-invasive approach for treating patients with depression that’s resistant to medical treatment, focused ultrasound is a non-radiation treatment that eliminates the risks of open neurosurgery.
The patient in Korea is part of a 10-patient clinical trial to determine the feasibility and safety of MR-guided focused ultrasound to destroy a small amount of tissue deep within the brain called the anterior limb of the internal capsule. This study is led by Dr. Jin Wood Chang, a neurosurgeon at Yonsei University College of Medicine in Seoul, Korea.
“There is a need for non-invasive treatment options for patients with depression that cannot be managed through medication,” said Chang, who is also president of the Korean Neurosurgical Society. “We were able to conduct the focused ultrasound procedure without complications or serious adverse effects. We will continue to monitor the patient to assess how her depression symptoms change over time.”
The advantage of focused ultrasound is that it’s being applied to the same targets within the brain that surgeons have used in the past, said Cosgrove. The big difference with using focused ultrasound to treat severely depressed patients is surgeons won’t need to put electrodes through the brain and patients won’t have to experience all the potential consequences of an invasive procedure.
Lasting between 4 to 6 hours, the procedure requires that the patient be shaved bald, according to Cosgrove. It begins with the application of a local anesthetic to “freeze” the patient’s scalp and a frame is then attached to the head to keep it from moving around within the MR machine. Then the patient is placed in the MR and a fluid-filled bladder is attached to their head. The patient then lies in the machine for the duration of the procedure, which entails the surgeon making lesions using focused ultrasound—which they can view in real time via the MR. Cosgrove said patients may feel some heat, though they don’t experience any pain or discomfort during the procedure.
“Unlike most interventions, we don’t expect to see any immediate results from the surgery,” he said. “It could take months to a year to see those improvements. The benefit continues to grow over time.”
Still, Cosgrove noted that this procedure isn’t curative. “[Patients] don’t get off medications. This isn’t a cure; it’s an aid to the treatment of these patients,” he said.
Cosgrove is optimistic that focused ultrasound can be used with patients with severe depression in the United States. “There have been discussions about considering using the device here. Of course, [this] has to be a multidisciplinary approach. And it all has to have [Institutional Review Board] approval and [Federal Drug Administration] approval because it’s a new technology. I hope to be able to use focused ultrasound for patients with these indications in the future,” he said.
This clinical trial is supported by the Focused Ultrasound Foundation. Founded in 2006, the organization describes itself as the largest non-governmental source of funding for focused ultrasound research. Its goal is to “improve the lives of millions of people around the world by accelerating the development of focused ultrasound.” Patients in the clinical trial are treated with focused ultrasound using Israel-based Insightec’s Exablate Neuro System.